Education
About Us
Working with TipRanks
Follow Us
Sangamo Biosciences (SGMO)
:SGMO
Earnings Data
Report Date
Apr 30, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.09Last Year’s EPS
-0.27Same Quarter Last Year
Moderate Buy
Based on 7 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 17, 2025
|% Change Since: -18.81%
|Next Earnings Date:Apr 30, 2025
Earnings Call Sentiment|Neutral
The call highlighted significant progress in Sangamo's neurology pipeline and strategic partnerships, along with financial achievements. However, challenges remain in securing a Fabry commercial partner and addressing financing needs, which are critical for future success.Company Guidance
During the Sangamo Therapeutics Fourth Quarter and Full Year 2024 teleconference call, the company provided guidance on several key metrics and upcoming milestones. Sangamo highlighted progress in their neurology pipeline, including securing their first neurology IND for idiopathic small fiber neuropathy and advancing a product candidate for prion disease. They announced collaborations with Genentech and Astellas for neurotrophic capsids, which could enhance delivery mechanisms for their therapies. Financially, Sangamo reduced non-GAAP operating expenses by nearly half since 2023 and raised over $100 million through license fees, milestone payments, and equity financing in 2024. The company emphasized the potential for accelerated approval of their Fabry disease gene therapy, which could shorten the approval timeline by approximately three years, with pivotal data expected in mid-2025. They are also negotiating to secure a commercial partner for their Fabry program, with an anticipated partnership in the second quarter of 2025. Additionally, Sangamo is in advanced contract negotiations for a third STAC-BBB license agreement, with potential news by the end of the quarter. The company aims to address its financing needs to support continued growth and development of its therapeutic programs.Progress in Neurology Therapies
Sangamo has advanced its prioritized neurology therapies towards the clinic, securing its first-ever neurology IND in idiopathic small fiber neuropathy and demonstrating non-clinical proof of concept for a product candidate in prion disease.
Strategic Partnerships
Sangamo announced two blue-chip pharma agreements for neurotrophic capsids with Genentech and Astellas, expanding their neurology disease targets.
Fabry Disease Gene Therapy Advancements
Sangamo's Fabry gene therapy study continues to generate best-in-class data, with a pivotal data readout expected in mid-2025. The FDA has provided a clear regulatory pathway to accelerated approval.
Financial Achievements
Since 2023, Sangamo has reduced non-GAAP operating expenses by nearly half year-over-year and raised over $100 million in funding through non-dilutive license fees, milestone payments, and equity financing.
ST-503 Development for Chronic Neuropathic Pain
ST-503 is ready to enter the clinic, targeting Nav1.7 sodium channels in sensory neurons, with promising preclinical results showing significant reduction in pain hypersensitivity.
---
SGMO Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SGMO Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 17, 2025 | $1.01 | $0.85 | -15.84% |
| Nov 12, 2024 | $2.71 | $2.44 | -9.96% |
| Aug 06, 2024 | $0.99 | $0.86 | -13.13% |
| May 09, 2024 | $0.52 | $0.56 | +7.69% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Sangamo Biosciences (SGMO) report earnings?
Sangamo Biosciences (SGMO) is schdueled to report earning on Apr 30, 2025, TBA Not Confirmed.
What is Sangamo Biosciences (SGMO) earnings time?
Sangamo Biosciences (SGMO) earnings time is at Apr 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SGMO EPS forecast?
SGMO EPS forecast for the fiscal quarter 2025 (Q1) is -0.09.
---